Trial Profile
The efficacy of talymus ophthalmic suspension in the treatment of ocular autoimmune disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Apr 2021
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Eye disorders
- Focus Therapeutic Use
- 16 Apr 2021 Status changed from active, no longer recruiting to completed.
- 23 Oct 2018 New trial record